Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema
Operational updates
Pharming Group announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Their official appointments will be confirmed by the Company’s Annual General Meeting of Shareholders that will be held on 19 May 2021.
New program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease
Pharming Group N.V. today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair.
Pharming Group N.V. announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).
Pharming Group N.V. announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.
Pharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).
Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.